Pfizer has been steadily reducing its stake in
Sensodyne toothpaste-maker Haleon, intending to cut holdings from 32% to 24%. The sales have amounted to several billions, with one transaction reaching $3.5 billion. Amidst these transactions,
First Trust Direct Indexing increased their holdings in the consumer health firm.
Haleon’s Q1 earnings have responded to market pressures. However, its shares have risen due to strong annual results and a
share buyback scheme. This has led to the speculation that the stock is approaching the end of its correction phase. Despite having to witness revenue declines and shutting down a UK plant with consequential job losses,
Haleon has managed to maintain traction in the market. Commenting on this,
GSK has managed to raise over a billion from its Haleon stake sale. Earnings continue to beat expectations, and despite
North America dragging on revenue estimates, the pharma giant sees stronger growth ahead with accelerated revenue growth at the end of last year. However, these developments have spurred in some market participants, such as Fisher Asset Management, to cut stock holdings in
Haleon. With a pending recall of some adult cough syrups due to contamination, the future of
Haleon will be closely watched.
Haleon Stocks News Analytics from Thu, 15 Jun 2023 07:00:00 GMT to Thu, 09 May 2024 11:52:25 GMT -
Rating 6
- Innovation 2
- Information 6
- Rumor 4
